Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189361 | 1.00 | EPHX1 (0.57) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL671402 | 1.00 | EPHX1 (0.57) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| Hydrochloric Acid SCHEMBL2500609 | 0.98 | EPHX1 (0.56) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| Hydrochloric Acid SCHEMBL2495441 | 0.98 | EPHX1 (0.56) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL2026360 | 0.90 | EPHX1 (0.55) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL556321 | 0.90 | EPHX1 (0.55) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL2024838 | 0.90 | EPHX1 (0.55) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL215297 | 0.90 | EPHX1 (0.65) | EPHX1ALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL2069710 | 0.89 | EPHX1 (0.57) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL6758420 | 0.89 | EPHX1 (0.57) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388569-A1 | HETEROCYCLIC COMPOUND FOR INHIBITING AND/OR INDUCING DEGRADATION OF KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4665458-A1 | INHIBITING ALPHA V BETA8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4139299-B1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-12-17 | — | — | EP | disclosed |
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4067344-B1 | CYCLOALKYL UREA DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2025-11-26 | — | — | EP | disclosed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12358910-B2 | Heteroaromatic compounds as Vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-07-15 | — | — | US | disclosed |
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-2050735-A1 | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-NITROGENATED COMPOUND | Kaneka Corporation (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-1343503-B1 | HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008130569-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| US-7309704-B2 | Heteroaryl urea neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309704-B2 | Heteroaryl urea neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION (US) | 2007-12-18 | — | — | US | disclosed |
| US-20050176738-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | LABORATORIOS VITA, S.A. (ES) | 2004-07-29 | — | — | US | disclosed |
| US-5866564-A | STABILITY | SANKYO COMPANY, LIMITED (JP) | 1999-02-02 | — | — | US | disclosed |
| US-5712267-A | Carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY,. LIMITED (JP) | 1998-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358910-B2 | Heteroaromatic compounds as Vanin inhibitors | VHL, FANCI, PAH | EPHX1 1284/4885USP30 3167/4885ALDH1A1 543/4885 |
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | AOC3, AOC2, TPH2 | EPHX1 677/4885USP30 3226/4885ALDH1A1 730/4885 |
| US-20050176738-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | MCHR1, MCHR2, MC1R | EPHX1 515/4885USP30 1859/4885ALDH1A1 1368/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | EPHX1 1898/4885USP30 1382/4885ALDH1A1 3319/4885 |
| US-20250388569-A1 | HETEROCYCLIC COMPOUND FOR INHIBITING AND/OR INDUCING DEGRADATION OF KRAS PROTEIN | KRAS, NRAS, HRAS | EPHX1 1897/4885USP30 2649/4885ALDH1A1 3855/4885 |
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | OXA1L, Q6ZSR9, PGC | EPHX1 2356/4885USP30 4108/4885ALDH1A1 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.